Statement of Deficiencies	**(X1) Provider/Supplier/CLIA Identification Number**	**(X3) Date Survey Completed**
	34D0925869	05/12/2021
Name of Provider or Supplier	**Street Address, City, State**	
Cpn, Inc Dba Atrium Health Levine Childrens	14214 Ballantyne Lake Road, Suite 300, Charlotte, NC	

For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D2016	SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on desk review of 2020 and 2021 CAP (College of American Pathologists) proficiency testing results and desk review of CMS (Centers for Medicare and Medicaid Services) Casper reports 153D and 155D on 5/12/21, the laboratory failed to achieve satisfactory performance for the specialty of routine chemistry on two of three consecutive testing events, resulting in unsuccessful participation. See the deficiency cited at D2097.
D2097	ROUTINE CHEMISTRY

	CFR(s): 493.841(g) Failure to achieve an overall testing event score of satisfactory performance for two consecutive testing events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on desk review of 2020 and 2021 CAP (College of American Pathologists) proficiency testing results and CMS (Centers for Medicare and Medicaid Services) Casper reports 153D and 155D on 5/12/21, the laboratory failed to achieve satisfactory performance for the specialty of routine chemistry on two of three consecutive testing events. Findings: 1. Desk review of 2020 CAP proficiency testing results and Casper report 155D revealed the laboratory received a score of 60% for total neonatal bilirubin, resulting in a score of 60% for the specialty of routine chemistry on the 2020 NB-B test event. 2. Desk review of 2021 CAP proficiency testing results and Casper report 155D revealed the laboratory received a score of 0% for total neonatal bilirubin, resulting in a score of 0% for the specialty of routine chemistry on the 2021 NB-A test event.
D6000	MODERATE COMPLEXITY LABORATORY DIRECTOR CFR(s): 493.1403 The laboratory must have a director who meets the qualification requirements of 493. 1405 of this subpart and provides overall management and direction in accordance with 493.1407 of this subpart. This CONDITION is not met as evidenced by: Based on desk review of 2020 and 2021 CAP (College of American Pathologists) proficiency testing results and CMS (Centers for Medicare and Medicaid Services) Casper reports 153D and 155D on 5/12/21, the laboratory director failed to provide overall management and direction to ensure successful participation in proficiency testing. See the deficiency cited at D6016.
D6016	LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(e)(4)(i) The laboratory director is responsible for the overall operation and administration of the laboratory, including the employment of personnel who are competent to perform test procedures, and record and report test results promptly, accurate, and proficiently and for assuring compliance with the applicable regulations. (e) The laboratory director must-- (e)(4)(i) Ensure that the proficiency testing samples are tested as required under Subpart H of this part; This STANDARD is not met as evidenced by: Based on desk review of 2020 and 2021 CAP (College of American Pathologists) proficiency testing results and CMS (Centers for Medicare and Medicaid Services) Casper reports 153D and 155D on 5/12/21, the laboratory director failed to ensure successful participation in proficiency testing as required in Subpart H. Findings: 1. Desk review of 2020 CAP proficiency testing results and Casper report 155D revealed the laboratory received a score of 60% for total neonatal bilirubin, resulting in a score

	of 60% for the specialty of routine chemistry on the 2020 NB-B test event. 2. Desk review of 2021 CAP proficiency testing results and Casper report 155D revealed the laboratory received a score of 0% for total neonatal bilirubin, resulting in a score of 0% for the specialty of routine chemistry on the 2021 NB-A test event.